Updates in Genetic Testing Guidelines for Breast Cancer Susceptibility Genes: a Change in the Paradigm

[1] Miki Y(1994)A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 266 66-71

[2] Swensen J(1995)Identification of the breast cancer susceptibility gene BRCA2 Nature 378 789-792

[3] Shattuck-Eidens D(2012)Comprehensive molecular portraits of human breast tumours Nature 490 61-70

[4] Futreal PA(2012)BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian Cancer study group J Clin Oncol 30 2654-2663

[5] Harshman K(1996)Genetic testing for cancer susceptibility, adopted on February 20 J Clin Oncol, 1996 14 1730-1736

[6] Tavtigian S(2003)Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 643-646

[7] Liu Q(2011)Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing Proc Natl Acad Sci U S A 108 18032-18037

[8] Cochran C(2010)Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality JAMA 304 967-975

[9] Bennett LM(2010)Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 235-244

[10] Ding W(2010)Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing Proc Natl Acad Sci U S A 107 12629-12633

[1] Miki Y(1994)A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 266 66-71

[2] Swensen J(1995)Identification of the breast cancer susceptibility gene BRCA2 Nature 378 789-792

[3] Shattuck-Eidens D(2012)Comprehensive molecular portraits of human breast tumours Nature 490 61-70

[4] Futreal PA(2012)BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian Cancer study group J Clin Oncol 30 2654-2663

[5] Harshman K(1996)Genetic testing for cancer susceptibility, adopted on February 20 J Clin Oncol, 1996 14 1730-1736

[6] Tavtigian S(2003)Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 643-646

[7] Liu Q(2011)Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing Proc Natl Acad Sci U S A 108 18032-18037

[8] Cochran C(2010)Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality JAMA 304 967-975

[9] Bennett LM(2010)Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 235-244

[10] Ding W(2010)Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing Proc Natl Acad Sci U S A 107 12629-12633